ASLAN Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASLN research report →
Price Chart
About the company
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions.
- CEO
- Carl Alan Jason Morton Firth EMBA,
- IPO
- 2018
- Employees
- 35
- HQ
- Singapore, SG
Get TickerSpark's AI analysis on ASLN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $777.12M
- P/E
- -0.06
- PEG
- -0.00
- P/S
- 64.76
- P/B
- -0.19
- EV/EBITDA
- -19.86
- Div Yield
- 0.00%
- Gross Margin
- 97.10%
- Op Margin
- -364.46%
- Net Margin
- -368.50%
- ROE
- 1796.92%
- ROIC
- -323.05%
Latest fiscal year · YoY change
- Revenue
- $12.00M+0.0%
- Gross Profit
- $11.65M+3612.1%
- Op Income
- $-43,735,600
- Net Income
- $-44,219,604+13.9%
- EPS
- $-10.76+26.9%
- OCF Growth
- -20.7%
- FCF Growth
- -20.7%
- 52W High
- $17.04
- 52W Low
- $0.47
- 50D MA
- $1.07
- 200D MA
- $3.48
- Beta
- 1.40
- RSI (14)
- 22
- Avg Volume
- 102.49K
No earnings-call transcripts are available for ASLN yet.
- Free Float
- 31.7%
- Shares Outstanding
- 323.80M
- Float Shares
- 102.58M
of shares held by institutions
1 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Knott David M | 478.19K | 0 |
Our ASLN coverage
Recent articles, reports, and earnings notes.
No research on ASLN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASLN report →Critical Contrast: ASLAN Pharmaceuticals (NASDAQ:ASLN) vs. Argos Therapeutics (OTCMKTS:ARGSQ)
defenseworld.net · Mar 23
Analyzing ASLAN Pharmaceuticals (NASDAQ:ASLN) & CannTrust (OTCMKTS:CNTTF)
defenseworld.net · Mar 21
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
globenewswire.com · Jul 17
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
globenewswire.com · Jul 15
All You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy
zacks.com · Jun 4
Here's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher
zacks.com · Jun 4
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
globenewswire.com · May 21
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com · May 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.